GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023.
- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023.
- With the addition of a time-based analysis, the company now expects to report topline results by the end of Q2 2024.
- In May 2023, FDA agreed to the initial Pediatric Study Plan (iPSP) submitted by GlycoMimetics.
- Second Quarter 2023 Financial Results:
Cash position: As of June 30, 2023, GlycoMimetics had cash and cash equivalents of $58.0 million as compared to $47.9 million as of December 31, 2022.